Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Trastuzumab Better Than Lapatinib in HER-2 Positive Breast Cancer | |
|
| |
Addition of
lapatinib to other anticancer drugs in HER-2 positive breast cancer patients
appears to be less effective than addition of trastuzumab, according to a
recent German study.
Breast cancer is the most common cancer affecting women the world over. Depending on the stage of the cancer, it is treated with either surgery, chemotherapy, radiotherapy or a combination of these treatments.
Chemotherapy in breast cancer may be administered as adjuvant therapy or neoadjuvant therapy. As adjuvant therapy, it is given after the primary treatment like surgery to prevent recurrence of the cancer. In neoadjuvant chemotherapy, the medications are given before the surgery. This is done to shrink the tumor before it can be surgically removed.
A number of anti-cancer drugs are used in the treatment of breast cancer; trastuzumab and lapatinib are among the newer drugs. Trastuzumab targets cells that produce too much of HER-2 or are HER-2 positive. HER-2 or the Human Epidermal growth factor Receptor 2 is responsible for cellular growth and proliferation. Cancers that are HER-2 positive have a poor outcome and are likely to recur. Lapatinib is another drug used in the treatment of HER-2 positive breast cancer.
In a recent study, the benefits and adverse effects of trastuzumab and lapatinib were compared when used in HER-2 positive breast cancer along with other anticancer drugs as neoadjuvant treatment.
In the study conducted on 620 HER-2 positive breast cancer patients, the patients received 4 cycles of the chemotherapeutic drugs epirubicin plus cyclophosphamide and 4 cycles of docetaxel. In addition to the chemotherapy, 309 patients received trastuzumab and 311 patients received lapatinib.
The researchers found that 30.3% patients in the trastuzumab group and 22.7% patients in the lapatinib group responded to treatment. Trastuzumab treatment was more frequently associated with edema and breathlessness, whereas treatment with lapatinib was more frequently associated with diarrhea and skin rash. The number of patients discontinuing lapatinib treatment was more than double that of those discontinuing trastuzumab (33.1% versus 14%), with 70 serious adverse effects in the trastuzumab group and 87 in the lapatinib group.
The study thus concluded that addition of trastuzumab to other chemotherapy drugs as neoadjuvant treatment in HER-2 positive breast cancer may be more effective and safer than using lapatinib.
Reference:
1. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial; Prof Michael Untch et al; The Lancet Oncology Jan 2012.
Source-Medindia
| |
|
|
More News on: Women and Cancer, Pagets disease of the breast, Mastitis, Cancer and Homeopathy, Breast Cancer Facts, Cancer Facts, Cancer, Tattoos A Body Art, Breasts - Structures and Types, Breast Lumps
 Comment & Contribute
|
Related Links
Lapatinib
This medication is a protein-tyrosine kinase inhibitor, prescribed for metastatic breast cancer with other ...
Trastuzumab
This medication is a monoclonal antibody, prescribed for breast cancer either alone or in combination with other medications. It kills cancer ...
Breast Cancer
Breast cancer is one of the oldest cancers known to man. It is the second most popular cancer after lung cancer and is the most common cancer amongst ...
Breast Cancer Facts and Figures
Breast cancer is the most commonly diagnosed cancer in women and in 2007 - 1.7 million breast cancers were diagnosed in the ...
Health Watch News
Stroke Survivors Need Emotional Support
Stroke is a condition characterized by death of brain cells due to inadequate supply of oxygen to brain cells. It can be of two types-hemorrhagic ...
Red Hair Pigment May Increase Risk of Melanoma, Skin Cancer
Fair skin is associated with increased risk of skin cancer. However, recent animal studies reveal that factors other than UV radiations are ...
Depression can be Treated by Deep Brain Stimulation
Deep Brain Stimulation may be used to treat depression, reveal new studies. Deep Brain Stimulation is a technique in which a ...
How Much Vitamin D is Needed for Infants?
We all know very well that vitamin D or 'the sunshine vitamin' is required for the growth and development of healthy bones. In the initial ...
You Will Invite Hatred by Fat Talk
You might be conscious about being overweight but make a point to avoid talking about your obesity with others, as nobody likes it or is interested ...
Dual Parenting More Beneficial Than Single Parenting, Shows Brain Research
Canadian research suggests that dual parenting may be more beneficial than single parenting. It may offer the advantage of enhancing brain cell ...
- Health News Index
 | Quiz on Cancer Looking for information on cancer? Go through medindia's Cancer quiz. 
|
- News Quick Links
 | News Central | | Health Watch | |
| Latest Health News | | Health In Focus | |
| News Category (500+) | | Breaking Health News | |
| Popular News | | Celebrating Life | |
| Health News and Press Release | | Medindia - Exclusive | |
| News Photo Gallery | | India Special | |
| News Video Gallery | | Lifestyle and Wellness | |
| News From Other Resources | |||
 |
Breast
Complete Medindia Resources
|
| News Categories: |
| » | India Gets Advanced Breast Cancer Detecting Machine |
| » | New Method can Help Distinguish Pancreatic Cancer from Pancreatitis |
| » | Link Between Agent Orange Exposure and Prostate Cancer |
| » | Tumour Growth Mechanism Goes a Step Further |
| » | Link Between Skin Cancer and Lower Risk of Alzheimer's Disease Identified |
| More Cancer News | |
|
Ask an Expert
